Welcome to our dedicated page for Igm Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on Igm Biosciences stock.
IGM Biosciences has reported strategic and clinical updates for engineered IgM antibody programs, with a recent focus on autoimmune and inflammatory diseases. Company developments have included pipeline pivots, discontinuation of imvotamab and IGM-2644, restructuring actions, workforce reductions, governance changes, quarterly operating results, capital resources, and investor conference presentations.
Updates have also addressed bispecific T cell engager candidates, including imvotamab as a CD20 x CD3 program and IGM-2644 as a CD38 x CD3 program, as well as clinical disclosures in autoimmune indications such as rheumatoid arthritis and systemic lupus erythematosus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on April 26, 2023, at 3:00 p.m. EDT. The event will be streamed live through the company’s Investors section on their website. A replay will be available for 90 days post-event.
IGM Biosciences focuses on developing engineered IgM antibodies to treat cancer, autoimmune diseases, and infectious diseases. Their unique technology allows for antibodies with 10 binding sites, surpassing conventional IgG antibodies, which have only 2 binding sites. The company also has an exclusive agreement with Sanofi to create IgM antibody agonists targeting oncology and immunology.
Medivir AB (NASDAQ Stockholm: MVIR) announced a presentation at the AACR Annual Meeting on April 17, 2023, highlighting a poster titled 'A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo.' Fostrox, an orally administered prodrug for liver-targeted therapy, is undergoing a phase 1/2a clinical study for advanced hepatocellular carcinoma (HCC) in combination with Keytruda® and Lenvima®. Data suggests that this triple combination may enhance anti-tumor effects, showing increased tumor infiltration of CD8+ T cells and PD-L1 expression. Medivir aims to address the significant unmet medical need in HCC treatment, as current therapies often fail to provide satisfactory results for many patients.
IGM Biosciences has announced the presentation of six posters highlighting data from their oncology pipeline during the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. Key presenters, including the Chief Medical Officer Chris Takimoto, emphasized the potential anticancer activity and favorable safety profiles of their compounds, including IGM-8444, IGM-7354, IGM-2644, IGM-2537, and imvotamab. The presentations will cover various innovative therapies, focusing on the effectiveness of bispecific IgM antibodies in treating cancers like acute myeloid leukemia and multiple myeloma. IGM's ongoing clinical trials aim to advance these therapies and demonstrate their benefits to patients. The Company is also collaborating with Sanofi to develop additional IgM antibody treatments.
Medivir AB (NASDAQ Stockholm: MVIR) has announced the availability of its Annual Report for 2022 on its website. The report highlights significant progress in the clinical development of fostrox, a potential first-line treatment for liver cancer, which commenced Phase 2a trials in early 2023. The recruitment rate for this trial was notably high in the latter half of 2022. Additionally, several out-licensed projects are progressing positively and are anticipated to enter clinical development in 2023. The Annual Report encompasses insights into the company's innovative drug development strategy focused on addressing unmet medical needs in cancer treatment.